Zhai Xu, Li Shi-Jun
Clinical Laboratory Diagnostics, Graduate School, Dalian Medical University, Dalian, China E-mail :
Asian Pac J Cancer Prev. 2014;15(12):4925-8. doi: 10.7314/apjcp.2014.15.12.4925.
This study aimed to evaluate the methylation of RASSF1A and CDH13 gene promoter regions as a marker for monitoring chemotherapeutic efficacy with personalized medicine for patients with NSCLC, in the hope of providing a new direction for NSCLC individualized chemotherapy.
42 NSCLC patients and 40 healthy controls were included. Patient blood samples were collected in the whole process of chemotherapy. Methylation of RASSF1A and CDH13 gene promoter regions was detected by the methylation specific polymerase chain reaction (MSP).
The rate of RASSF1A and CDH13 gene methylation in 42 cases of NSCLC patients was significantly higher than in 40 healthy controls (52.4% to 0.0%, 54.8% to 0.0%, p<0.05). After the chemotherapy, the hyper-methylation of RASSF1A and CDH13 genes in PR group and SD group decreased significantly (p<0.05), and was significantly different from that in PD group (p<0.05), but not as compared with healthy controls (P>0.05). With chemotherapy, RASSF1A and CDH13 promoter region methylation rate in 42 cases of patients showed a declining trend.
The methylation level of RASSF1A and CDH13 gene promoter region can reflect drug sensitivity of tumors to individualized treatment.
本研究旨在评估RASSF1A和CDH13基因启动子区域的甲基化作为监测非小细胞肺癌（NSCLC）患者个体化化疗疗效的标志物，以期为NSCLC个体化化疗提供新方向。
纳入42例NSCLC患者和40例健康对照。在化疗全过程采集患者血样。采用甲基化特异性聚合酶链反应（MSP）检测RASSF1A和CDH13基因启动子区域的甲基化。
42例NSCLC患者的RASSF1A和CDH13基因甲基化率显著高于40例健康对照（分别为52.4%对0.0%，54.8%对0.0%，p<0.05）。化疗后，PR组和SD组中RASSF1A和CDH13基因的高甲基化显著降低（p<0.05），且与PD组有显著差异（p<0.05），但与健康对照相比无差异（P>0.05）。随着化疗进行，42例患者中RASSF1A和CDH13启动子区域甲基化率呈下降趋势。
RASSF1A和CDH13基因启动子区域的甲基化水平可反映肿瘤对个体化治疗的药物敏感性。
